Literature DB >> 31134494

Heterogeneity of Small Cell Lung Cancer Stem Cells.

D Prabavathy1, Niveditha Ramadoss2.   

Abstract

Small cell lung cancer, a subtype of lung cancer is an extremely malignant disease due to its metastases and recurrence. Patients with SCLC develop resistance to chemotherapy and the disease relapses. This relapse and resistance are attributed to the heterogeneity of SCLC. Various factors such as recurrent mutations in key regulatory genes such as TP53, RB1, and myc, epigenetic changes, and cancer stem cells contribute to the observed heterogeneity. Cancer stem cell models predict neuroendocrine origin of SCLC. Though an unambiguous established CSC marker has not been assigned, markers CD133, CD44 have been found associated with SCLC. Genetically engineered mouse models (GEMMs) allow the validation of driver mutations and are necessary for design of targeted therapy. This chapter outlines the factors contributing to SCLC heterogeneity, detection methods, and the current therapy trials.

Entities:  

Keywords:  CD133; CD44; CSC model; Clonal evolution; Genetically engineered mouse model; Intratumor heterogeneity; Lysine demethylase 1; Neuroendocrine markers; Notch pathway; RB1; SCLC; Side population cells; TP53

Mesh:

Year:  2019        PMID: 31134494     DOI: 10.1007/978-3-030-14366-4_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival.

Authors:  Hiroshi Yokouchi; Hiroshi Nishihara; Toshiyuki Harada; Shigeo Yamazaki; Hajime Kikuchi; Satoshi Oizumi; Hidetaka Uramoto; Fumihiro Tanaka; Masao Harada; Kenji Akie; Fumiko Sugaya; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Mitsunori Higuchi; Osamu Honjo; Yoshinori Minami; Naomi Watanabe; Masaharu Nishimura; Hiroyuki Suzuki; Hirotoshi Dosaka-Akita; Hiroshi Isobe
Journal:  Heliyon       Date:  2020-07-13

2.  Colony‑stimulating factor CSF2 mediates the phenotypic plasticity of small‑cell lung cancer by regulating the p‑STAT3/MYC pathway.

Authors:  Hui Li; Rui Zhong; Chunying He; Chenchen Tang; Heran Cui; Rixin Li; Yan Liu; Shaowei Lan; Ying Cheng
Journal:  Oncol Rep       Date:  2022-05-18       Impact factor: 4.136

Review 3.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 4.  The Role of Tumor Stem Cell Exosomes in Cancer Invasion and Metastasis.

Authors:  Kun Liu; Xin Gao; Baoqiang Kang; Yunpeng Liu; Dingding Wang; Yi Wang
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

5.  Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.

Authors:  Yanhua Tian; Qingqing Li; Zhenlin Yang; Shu Zhang; Jiachen Xu; Zhijie Wang; Hua Bai; Jianchun Duan; Bo Zheng; Wen Li; Yueli Cui; Xin Wang; Rui Wan; Kailun Fei; Jia Zhong; Shugeng Gao; Jie He; Carl M Gay; Jianjun Zhang; Jie Wang; Fuchou Tang
Journal:  Signal Transduct Target Ther       Date:  2022-10-05

6.  The molecular mechanism of long non-coding ribonucleic acid (lncRNA) RUNX1-IT1 promotes the proliferation and stemness of lung cancer cells.

Authors:  Yajun Miao; Tao Li; Yufei Liu; Yong Yu; Jianqiu Wu
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

7.  MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway.

Authors:  Massimo Moro; Orazio Fortunato; Giulia Bertolini; Mavis Mensah; Cristina Borzi; Giovanni Centonze; Francesca Andriani; Daniela Di Paolo; Patrizia Perri; Mirco Ponzoni; Ugo Pastorino; Gabriella Sozzi; Mattia Boeri
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.